Sign in

NCT07559565Not yet recruiting

Migraine is Associated With Altered Mechanical Pain Sensitivity. This Study Investigates Mechanical Pain Sensitivity, Headache Burden, and Quality of Life in Episodic and Chronic Migraine, Comparing Pressure Algometry and Algopeg® and Assessing Mechanosensitivity of Peripheral Nerves.

Mechanical Pain Sensitivity, Headache Burden, and Quality of Life in Episodic and Chronic Migraine - A Cross-Sectional Study

Source: ClinicalTrials.gov · Last updated 30 Apr 2026

Brief summary (registry, in English)

Migraine is one of the most prevalent neurological disorders and is associated with a substantial individual and societal burden. In chronic migraine, central and peripheral sensitization mechanisms are considered key pathophysiological factors and may manifest, among other features, as altered mechanical pain sensitivity. Quantitative assessment of mechanical pain sensitivity using pressure algometry is an established method; however, it is partly dependent on examiner technique and measurement protocols. The Algopeg® represents a standardized instrument for assessing mechanical pain sensitivity and may serve as a practical complement or alternative to classical pressure algometry. To date, evidence regarding the use of the Algopeg® in migraine populations remains limited. In addition to increased mechanosensitivity in trigeminal and extra-trigeminal regions, peripheral nerve structures, such as branches of the greater occipital nerve and the supraorbital nerve, may show sensitivity to mechanical stimuli during neurodynamic testing or palpation. This may have clinical relevance, as these regions are often targeted in symptomatic and prophylactic treatments. The aim of this study is to systematically investigate mechanical pain sensitivity, headache-related outcomes, and quality of life in patients with episodic and chronic migraine. Furthermore, the study aims to compare pressure algometry and Algopeg® measurements and to explore the clinical relevance of mechanosensitivity in specific peripheral nerve regions using a standardized assessment protocol.

Status (registry)
Not yet recruiting
Study type
Observational
Enrollment
102 (estimated)
First submitted
17 Apr 2026
Start date
1 Jun 2026
Primary completion date
30 Sept 2026
Lead sponsor
Bernhard Taxer
Diseases
Migraine
NCT number
NCT07559565

What you commit to

  • Study type: Observational
  • Planned participants: 102
  • From 1 Jun 2026 to the primary completion date, 30 Sept 2026
  • 1 site in 1 country
  • Visits and tests: ask the trial team, the registry does not list them

Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.

Who cannot take part

Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.

Other illness

  • Other primary or secondary headache disorders
  • Severe neurological, psychiatric, or systemic diseases

Other

  • Pregnancy or breastfeeding
  • Participation in another (interventional) study within the last 3 months

Who the study is looking for

  • Female and male sex
  • Age 18-65 years
  • Diagnosis of episodic or chronic migraine according to ICHD-3 criteria (beta version)
  • Stable medication regimen (if applicable) for at least 4 weeks prior to inclusion
  • Ability to understand study procedures and provide written informed consent

Age in the registry: 18 years to 65 years · Sex: All · Accepts healthy volunteers

Full criteria on ClinicalTrials.gov

Sites (1)

Sites in registry order. Pick your city on the disease page to sort them by distance.

SiteCityCountrySite status
Universitätsklinik für Neurologie, neurologische Intensivmedizin und Neurorehabilitation
Coordinator of this site? Confirm its status
SalzburgAustriaUnknown status

This page is information, not medical advice. Discuss any trial with your doctor.